Natera and TransCode launch collaboration to enroll MRD‑positive colorectal cancer patients in Phase 2a trial
Natera Inc. and TransCode Therapeutics announced a partnership to use Natera’s Signatera circulating‑tumor‑DNA test for identifying colorectal cancer patients who are molecular residual disease‑positive after curative‑intent therapy and have no radiographic disease. Those patients will be enrolled in TransCode’s Phase 2a study of the investigational drug TTX‑MC138, which targets microRNA‑10b. The trial is conducted under the Quantum Leap Healthcare Collaborative’s PRE‑I‑SPY program and is the first expansion of that program beyond breast cancer.
Why it matters
The collaboration could increase demand for Signatera by extending its use to colorectal cancer, potentially boosting Natera’s revenue stream, while giving TransCode access to a defined high‑risk patient pool for its candidate therapy. No analyst commentary was provided in the materials.
Key facts
- 1The partnership was announced on Tuesday. investing.com
- 2Signatera will be used to select patients who are MRD‑positive after curative‑intent treatment and have no radiographic evidence of disease. investing.com
- 3The selected patients will be enrolled in TransCode’s Phase 2a trial of TTX‑MC138. investing.com
- 4The trial is registered on clinicaltrials.gov under identifier NCT05868226. investing.com
- 5The study is part of the PRE‑I‑SPY program run by Quantum Leap Healthcare Collaborative and marks the program’s first expansion beyond breast cancer. investing.com
- 6TTX‑MC138 is designed to inhibit microRNA‑10b, a biomarker linked to metastatic cancer development. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.